Which radiation approach spares prostate cancer Patients' bladder function?

NCT ID NCT02692105

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study compares two types of radiation therapy for men with favorable or low-tier intermediate risk prostate cancer: low dose rate (LDR) brachytherapy, which uses permanent radioactive seeds, and high dose rate (HDR) brachytherapy, which uses temporary radioactive material. The main goal is to see which approach better preserves urinary quality of life. Participants will be randomly assigned to one of the two treatments and followed for up to three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Low dose rate (LDR) brachytherapy with permanent radioactive seeds or high dose rate (HDR) brachytherapy with temporary radioactive material

What this could lead to

If successful, this trial could show that HDR brachytherapy offers better urinary quality of life than the current standard LDR brachytherapy for men with early-stage prostate cancer.

What could go wrong

This is a small pilot study with only 60 participants, so results may not apply to all patients. Both treatments involve radiation risks, and the trial may not find a meaningful difference in outcomes.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • British Columbia Cancer Agency Center for the Southern Interior

    Kelowna, British Columbia, V1Y5L3, Canada